Molecular mechanism and function of CD40/CD40L engagement in the immune system - PubMed (original) (raw)
Review
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Raul Elgueta et al. Immunol Rev. 2009 May.
Abstract
During the generation of a successful adaptive immune response, multiple molecular signals are required. A primary signal is the binding of cognate antigen to an antigen receptor expressed by T and B lymphocytes. Multiple secondary signals involve the engagement of costimulatory molecules expressed by T and B lymphocytes with their respective ligands. Because of its essential role in immunity, one of the best characterized of the costimulatory molecules is the receptor CD40. This receptor, a member of the tumor necrosis factor receptor family, is expressed by B cells, professional antigen-presenting cells, as well as non-immune cells and tumors. CD40 binds its ligand CD40L, which is transiently expressed on T cells and other non-immune cells under inflammatory conditions. A wide spectrum of molecular and cellular processes is regulated by CD40 engagement including the initiation and progression of cellular and humoral adaptive immunity. In this review, we describe the downstream signaling pathways initiated by CD40 and overview how CD40 engagement or antagonism modulates humoral and cellular immunity. Lastly, we discuss the role of CD40 as a target in harnessing anti-tumor immunity. This review underscores the essential role CD40 plays in adaptive immunity.
Figures
Fig. 1. CD40 signaling dependent and independent of tumor necrosis factor receptor-associated factor (TRAF) proteins
After CD40 activation, TRAFs 1, 2, 3, 5, and 6 are recruited to CD40 tail, driving different signaling pathways. Furthermore, Janus family kinase 3 can bind to the proximal cytoplasmic membrane of CD40. The signaling dependent or independent of TRAF protein regulates different cellular and immune processes.
Fig. 2. Role of tumor necrosis factor receptor-associated factors (TRAFs) 2 and 3 in the inhibition of non-canonical nuclear factor κB (NFκB) pathway
Under non-stimulation, TRAF2 and TRAF3 form a complex with cellular inhibitor of apoptosis 1 and 2 (cIAP1 and cIAP2) and NFκB-inducing kinase (NIK). cIAP1/2 degrades NIK, ablating the non-canonical NFκB pathway (39, 40). After CD40/CD40L engagement, the complex is destabilized, permitting the release of NIK from the complex inducing the non-canonical NFκB signaling. Furthermore, it induced the recruitment of TRAF2 and TRAF3 to CD40 tail and the degradation of TRAF3 by cIAP1/2 proteins.
Similar articles
- Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
Chand Dakal T, Dhabhai B, Agarwal D, Gupta R, Nagda G, Meena AR, Dhakar R, Menon A, Mathur R, Mona, Yadav V, Sharma A. Chand Dakal T, et al. Immunobiology. 2020 Mar;225(2):151899. doi: 10.1016/j.imbio.2019.151899. Epub 2019 Dec 17. Immunobiology. 2020. PMID: 31899051 Review. - Functions of CD40 and Its Ligand, gp39 (CD40L).
Laman JD, Claassen E, Noelle RJ. Laman JD, et al. Crit Rev Immunol. 2017;37(2-6):371-420. doi: 10.1615/CritRevImmunol.v37.i2-6.100. Crit Rev Immunol. 2017. PMID: 29773027 Review. - Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE. Li Q, et al. J Immunol. 2005 Aug 1;175(3):1424-32. doi: 10.4049/jimmunol.175.3.1424. J Immunol. 2005. PMID: 16034078 - Update on CD40 and CD154 blockade in transplant models.
Zhang T, Pierson RN 3rd, Azimzadeh AM. Zhang T, et al. Immunotherapy. 2015;7(8):899-911. doi: 10.2217/IMT.15.54. Epub 2015 Aug 13. Immunotherapy. 2015. PMID: 26268734 Free PMC article. Review. - Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, Baronas AR, Gergel LE, Boyer JM, Sisson C, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. doi: 10.1007/s00262-018-2267-0. Epub 2018 Oct 31. Cancer Immunol Immunother. 2019. PMID: 30382327 Free PMC article.
Cited by
- Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells.
Ohara D, Takeuchi Y, Hirota K. Ohara D, et al. Cell Mol Immunol. 2024 Oct 8. doi: 10.1038/s41423-024-01218-x. Online ahead of print. Cell Mol Immunol. 2024. PMID: 39379604 Review. - Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections.
Paranga TG, Pavel-Tanasa M, Constantinescu D, Iftimi E, Plesca CE, Miftode IL, Cianga P, Miftode E. Paranga TG, et al. Front Immunol. 2024 Sep 23;15:1464480. doi: 10.3389/fimmu.2024.1464480. eCollection 2024. Front Immunol. 2024. PMID: 39376569 Free PMC article. - Female-bias in systemic lupus erythematosus: How much is the X chromosome to blame?
Vieira AA, Almada-Correia I, Inácio J, Costa-Reis P, da Rocha ST. Vieira AA, et al. Biol Sex Differ. 2024 Oct 7;15(1):76. doi: 10.1186/s13293-024-00650-y. Biol Sex Differ. 2024. PMID: 39375734 Free PMC article. Review. - Tumor necrosis factor superfamily signaling: life and death in cancer.
Ababneh O, Nishizaki D, Kato S, Kurzrock R. Ababneh O, et al. Cancer Metastasis Rev. 2024 Oct 4. doi: 10.1007/s10555-024-10206-6. Online ahead of print. Cancer Metastasis Rev. 2024. PMID: 39363128 Review. - Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design.
Medina GN, Diaz San Segundo F. Medina GN, et al. Vaccines (Basel). 2024 Sep 19;12(9):1071. doi: 10.3390/vaccines12091071. Vaccines (Basel). 2024. PMID: 39340101 Free PMC article. Review.
References
- Quezada SA, et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307–328. - PubMed
- Bromley SK, et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol. 2001;2:1159–1166. - PubMed
- Au PY, Yeh WC. Physiological roles and mechanisms of signaling by TRAF2 and TRAF5. Adv Exp Med Biol. 2007;597:32–47. - PubMed
- Linsley PS, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule. Science. 1992;257:792–795. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials